Where does Cyclerion Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cyclerion Therapeutics, Inc. ranks #12,397 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cyclerion Therapeutics, Inc. hold?

Cyclerion Therapeutics, Inc. holds 24 US utility patents granted between 2019 and 2025, spanning 7 technology areas.

What is Cyclerion Therapeutics, Inc.'s Innovation Score?

Cyclerion Therapeutics, Inc. has an Innovation Score of 38.2 out of 100 (top 41% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cyclerion Therapeutics, Inc. focus on?

Cyclerion Therapeutics, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 20 patents, ranking #448 of 3,165 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Cyclerion Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Cyclerion Therapeutics, Inc.'s recent grant velocity is +900% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Cyclerion Therapeutics, Inc.'s patents?

Cyclerion Therapeutics, Inc.'s patents average 13.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cyclerion Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Cyclerion Therapeutics, Inc.

USPTO PatentsView assignee record - 24 granted patents across 7 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cyclerion ranks #12,397 of 49,997 tracked US assignees by granted-patent volume, with 24 patents across 7 technology areas.

#12,397
of 49,997 US assignees by volume: Top 41%
by Innovation Score (38.2/100): 13.5
avg claims per patent: +900%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12397 · US Corporation #12,397 · 24 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 24 grants
UPPER-Q #12,397/49,997
PHOTO-FINISH for National…
CPC-NARROW C07D · 7 areas
INNOV-THIN 38.2/100
CLAIMS-RICH 13.5 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +900% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Corporation for National Research Initiatives (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cyclerion’s 38.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.1 pts (29%) Velocity 9.6 pts (25%) Breadth 9.4 pts (25%) Claim depth 8.1 pts (21%)

Qualcomm Incorporated · highest

85
Cyclerion Therapeutics · this assignee

38
3D Lighting… · lowest

7

What this shows Cyclerion's Innovation Score is 38.2/100 (top 41% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cyclerion?

Each dot is one of Cyclerion’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cyclerion’s own 13.5 claims/patent is at or below the 16.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Cyclerion vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cyclerion's grants concentrate

Cyclerion Therapeutics, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 83.3% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2022 (6 grants) versus a trough of 1 in 2024. By volume, Cyclerion sits between CorTec GmbH and Delfortgroup AG.

Cyclerion's three-year grant acceleration

Cyclerion Therapeutics, Inc. shows 13 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cortec

24
for National Rese…

24
Coviden

24
Cumberland Pharma…

24
Cyral

24
D-link

24
Deka Biosciences

24
Delfortgroup

24
Cyclerion Therape… ◀

24

What this shows Cyclerion holds 24 patents at rank #12,399, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cyclerion

By rank, the assignees closest to #12,399 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Cyclerion's primary technology class.

Cyclerion's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 41% higher than 59% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Cyclerion Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	2	8.3%
2020	3	12.5%
2021	4	16.7%
2022	6	25.0%
2023	6	25.0%
2024	1	4.2%
2025partial year	2	8.3%

Which technologies does Cyclerion Therapeutics, Inc. patent most?

C07D - Heterocyclic Compounds 20

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 17

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 7

C07C - Acyclic OR Carbocyclic Compounds 6

Y02A - Technologies FOR Adaptation TO Climate Change 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cyclerion Therapeutics, Inc.'s patent record in context - here's where to go next.

Cyclerion Therapeutics, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 83.3% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #12,397 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cyclerion Therapeutics, Inc. against CorTec GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.